Pacira Pharmaceuticals, Inc. (PCRX) to Release Quarterly Earnings on Tuesday
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) will announce its earnings results before the market opens on Tuesday, October 31st. Analysts expect the company to announce earnings of $0.03 per share for the quarter.
Pacira Pharmaceuticals (NASDAQ:PCRX) last released its earnings results on Wednesday, August 2nd. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.06). Pacira Pharmaceuticals had a negative return on equity of 12.44% and a negative net margin of 23.36%. The business had revenue of $70.90 million for the quarter, compared to analyst estimates of $73.37 million. During the same quarter in the previous year, the firm posted $0.21 EPS. The business’s revenue for the quarter was up 1.9% on a year-over-year basis. On average, analysts expect Pacira Pharmaceuticals to post $-0.94 EPS for the current fiscal year and $0.56 EPS for the next fiscal year.
Pacira Pharmaceuticals, Inc. (PCRX) opened at 32.95 on Tuesday. Pacira Pharmaceuticals, Inc. has a 52-week low of $29.95 and a 52-week high of $58.95. The firm’s 50-day moving average price is $36.22 and its 200 day moving average price is $42.27. The firm’s market cap is $1.33 billion.
ILLEGAL ACTIVITY NOTICE: “Pacira Pharmaceuticals, Inc. (PCRX) to Release Quarterly Earnings on Tuesday” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/24/pacira-pharmaceuticals-inc-pcrx-to-release-quarterly-earnings-on-tuesday.html.
A number of equities research analysts have recently weighed in on PCRX shares. Wedbush reaffirmed an “outperform” rating and set a $87.00 price target on shares of Pacira Pharmaceuticals in a report on Wednesday, August 23rd. Mizuho reiterated a “buy” rating and set a $54.00 price objective on shares of Pacira Pharmaceuticals in a research note on Wednesday, July 26th. ValuEngine lowered shares of Pacira Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. BidaskClub lowered shares of Pacira Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 2nd. Finally, Cowen and Company reiterated a “hold” rating on shares of Pacira Pharmaceuticals in a research note on Friday, July 14th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and ten have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $51.86.
In other Pacira Pharmaceuticals news, Director Paul J. Hastings sold 1,044 shares of Pacira Pharmaceuticals stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $36.15, for a total transaction of $37,740.60. Following the completion of the sale, the director now owns 3,518 shares of the company’s stock, valued at approximately $127,175.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Kristen Marie Williams sold 3,461 shares of Pacira Pharmaceuticals stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $36.75, for a total transaction of $127,191.75. Following the sale, the chief accounting officer now directly owns 21,312 shares of the company’s stock, valued at approximately $783,216. The disclosure for this sale can be found here. Insiders sold a total of 33,390 shares of company stock valued at $1,215,480 in the last ninety days. Company insiders own 6.60% of the company’s stock.
About Pacira Pharmaceuticals
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.